SynthesisJournal of the American Society of Nephrology : JASN2019
Quantity and Reporting Quality of Kidney Research.
Synthesis in Journal of the American Society of Nephrology : JASN, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Reporting quality and risk of bias of randomized controlled trials of Chinese herbal medicine for multiple sclerosis.Frontiers in immunology · 2024Pooled it
- Quality of reporting and risk of bias: a review of randomised trials in occupational health.Occupational and environmental medicine · 2021Pooled it
- Priorities for Evidence-Based CKD Guidance Using Delphi Methods.Kidney international reports · 2026Article
- Prescription of off-label medications in patients on dialysis: time to challenge contraindications?Clinical kidney journal · 2026Review
- Pre-Exposure Intranasal Treatment with Neomycin Sulfate Reduces Transmission of Influenza B Virus.Antibiotics (Basel, Switzerland) · 2026Article
- The Role of Analysis Populations and Estimands in Clinical Trials.Journal of the American Society of Nephrology : JASN · 2026Article
- Review no. 1: designing clinical kidney research using real-world data: research questions, data sources, and analytical skills.Clinical and experimental nephrology · 2026Review
- Oral Toxicity Profile of a Novel Silk Lutein Extract and Assessment of Its Cardiovascular Benefits in Rodents.International journal of molecular sciences · 2026Article
- Reporting Quality of Trend Analyses Published in Leading Medicine and Oncology Journals during 2008-2018.Exploratory research and hypothesis in medicine · 2025Article
- Reporting Quality of Randomized Controlled Trials in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.Kidney international reports · 2025Article
- Article
- Biological Effects of Polysaccharides fromPharmaceutics · 2025Article
- Investigating the Therapeutic Mechanisms of Total Saikosaponins in Alzheimer's Disease: A Metabolomic and Proteomic Approach.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Review of the target trial methodological approach on treatment effect estimates in kidney failure: protocol for a systematic assessment.Systematic reviews · 2024Article
- A cross-sectional analysis of reporting guideline and clinical trial registration policies in nephrology journals.Journal of nephrology · 2024Article
- Improved Wound Healing and Skin Regeneration Ability of 3,2'-Dihydroxyflavone-Treated Mesenchymal Stem Cell-Derived Extracellular Vesicles.International journal of molecular sciences · 2023Article
- Understanding the Current Landscape of Kidney Disease in Canada to Advance Precision Medicine Guided Personalized Care.Canadian journal of kidney health and disease · 2023Review
- Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials.Kidney international reports · 2022Review
- Ongoing Clinical Trials in Aging-Related Tissue Fibrosis and New Findings Related to AhR Pathways.Aging and disease · 2022Review
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2004, researchers reported that the number of nephrology clinical trials was low and that the reporting quality of such trials was suboptimal. Furthermore, the number or quality of preclinical kidney-related studies has not been systematically evaluated.
methodsWe performed a systematic review of randomized clinical trials published in 1966-2017 (listed in the Cochrane Library) and preclinical studies published in 1945-2017 (listed in PubMed). For reporting quality analysis, we evaluated the final main paper of 118 clinical trial reports and 135 preclinical studies published in leading journals in 1996, 2006, and 2016 on the basis of criteria from the widely used CONSORT and ARRIVE guidelines.
resultsThe annual number of reports of clinical kidney-related trials more than doubled between 2004 and 2014 along with reports in other medical disciplines. Hypertension remains the dominant focus of study, but ongoing trials also center on CKD, ESRD, and AKI. The reporting quality analysis revealed improvements, but deficits in reporting of clinical trial design, mode of randomization, and intention-to-treat analysis remain. Annual numbers of kidney-related preclinical studies remained low between 1945 and 2017 compared with other disciplines. Reporting quality analysis of preclinical studies revealed substantial reporting deficits across all leading journals, with little improvement over the last 20 years, especially for group size calculations, defining primary versus secondary outcomes, and blinded analysis.
conclusionsNephrology studies keep increasing in number but still lag behind other medical disciplines, and the quality of data reporting in kidney research can be further improved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.